Ardena forms partnership with RiboPro to improve mRNA-based therapies

Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. 

Ardena, a leading CDMO specialising in nanomedicines has teamed up with RiboPro, who focus on mRNA and LNP technology, to deliver improvements via a commercial partnership, in the availability of RNA-based therapies to a cGMP level, on a global scale. 

The combined skillset of the two companies fulfils an unmet need in the market, with Ardena’s experience in custom development and cGMP manufacturing of lipids and LNP-mRNA formulations combined with the mRNA technologies and expertise in mRNA synthesis and encapsulation from RiboPro. The partnership facilitates a seamless offering in end-to-end production of advanced mRNA and LNP formulations. 

This more efficient production process will help drug developers to work more quickly and efficiently, whilst minimising risks associated with scaling production and manufacturing, leader to greater outputs all while being more cost effective. 

Harry Christiaens, CEO of Ardena commented: 

“The availability of high-quality, stable, and non-immunogenic mRNA in combination with the formulation, process development, analytical development, and manufacturing capabilities of various LNP compositions is critical to achieving the desired payload, encapsulation, stability in circulation, in vivo transfection, and tissue-specific delivery. 

“By having all the expertise at the same table, the quality of the new therapeutic and its development plan will be higher from the start, maximising chances of positively impacting the patient.”

“The Ardena/RiboPro alliance will be a science-led and service-strong partnership covering the entire CDMO supply chain from advanced mRNA synthesis to aseptic fill and finishing. 

“In a highly competitive niche area of the market the Ardena/RiboPro alliance aspires to differentiate itself from the competition through its fully integrated, highly customer-centric approach. The combination of a state-of-the-art proprietary portfolio of mRNA and LNP technologies with over a decade of nanomedicine development expertise offers our customers an equally unique and beneficial service resulting in accelerated drug development programmes.”

“The strategic alliance with Ardena represents an exciting opportunity for RiboPro,” added Sander van Asbeck, CEO of RiboPro. “Our portfolio of proprietary technologies, and expertise in mRNA synthesis and encapsulation, combined with Ardena’s experience in process development and cGMP manufacturing, will provide our clients with a seamless pathway to advanced mRNA therapeutics with the ultimate goal of getting innovative medicines to patients sooner. 

“Our collaboration will also help RiboPro develop a deeper understanding of customer needs and create even more advanced mRNA and LNP solutions accordingly."

Source: Ardena. Ardena and RiboPro Forge Strategic Alliance to Support the RNA Revolution with End-to-End Manufacturing of Advanced mRNA and LNP Solutions. [Date accessed 11/07/2023].